Merck & Co., Inc. (MRK) Factsheet
Earnings-call transcript: none · IR deck: cataloged — watch a real agent read these end-to-end →
Merck & Co., Inc. (MRK) Stock Analysis
Analysis from 10-Q filed 2026-08-07. Data as of Q2 2026.
Overall Grade: F (Concerning)
Grade F (Concerning). ROIC 4.0%. FCF margin 24.1%. D/E 1.3x. Source: 10-Q filed 2026-08-07.
| Metric | Value | Context |
|---|---|---|
| ROIC | 4.0% | Below expectations |
| FCF Margin | 24.1% | Strong cash generation |
| Debt/Equity | 1.3x | Moderate leverage |
ROIC 4.0% — Top 50% of sector peers. FCF margin 24.1% — Top 10%.
Explore Merck & Co., Inc.: Earnings History | Filings
Programmatic access: Available via MCP at mcp.metricduck.com. Tools for MRK: get_company_overview, get_filing_index (lens: debt_stress, management_outlook, risk_trajectory), get_filing_changes, get_metric_history, compare_companies, screen_filing_signals.
Profitability: Merck & Co., Inc. earns 4.0% ROIC, Top 50% in Healthcare
ROIC TTM 4.0%, sector median -7.4%, Top 50%. DuPont: NOPAT margin 5.8% × asset turnover 0.5x. Gross margin 73.0%. Operating margin 10.5%. Source: 10-Q filed 2026-08-07.
| Metric | MRK | Rating | Context |
|---|---|---|---|
| Return on Invested Capital (ROIC) | 4.0% | Warning | Above sector median of -7.4% |
| Return on Equity (ROE) | 6.5% | Warning | Moderate equity returns |
| Gross Margin | 73.0% | Excellent | Strong pricing power |
| Operating Margin | 10.5% | Good | Moderate operational efficiency |
Cash Flow: Merck & Co., Inc. generates $16.1B FCF at 24.1% margin, positive NaN/8 quarters
FCF TTM $16.1B. FCF margin 24.1%, Top 10%. OCF/Net income 6.3x. Positive FCF in NaN/8 trailing quarters. Source: 10-Q filed 2026-08-07.
| Metric | MRK | Rating | Context |
|---|---|---|---|
| Free Cash Flow Margin | 24.1% | Excellent | Excellent cash conversion |
| Free Cash Flow (TTM) | $16.1B | Good | Positive cash generation |
| OCF/Net Income | 6.3x | Excellent | High earnings quality |
| FCF Consistency (8Q) | N/A | Warning | Variable cash flow |
Balance Sheet: Merck & Co., Inc. at 1.3x leverage, 4.0x interest coverage
Debt/Equity 1.3x. Total debt $53.9B, cash & investments $7.1B. Interest coverage 4.0x. Source: 10-Q filed 2026-08-07.
| Metric | MRK | Rating | Context |
|---|---|---|---|
| Debt to Equity | 1.3x | Adequate | Moderate leverage |
| Net Cash Position | $-46.8B | Warning | Net debt position |
| Interest Coverage | 4.0x | Adequate | Monitor debt obligations |
Valuation: Merck & Co., Inc. trades at 113.6x earnings
P/E 113.6x. EV/Sales 6.1x. FCF yield 4.5%. Dividend yield 2.3%. Source: 10-Q filed 2026-08-07.
| Metric | MRK | Rating | Context |
|---|---|---|---|
| P/E Ratio | 113.6x | Warning | Premium valuation |
| EV/Sales | 6.1x | Adequate | Growth premium priced in |
| FCF Yield | 4.5% | Good | Lower cash yield |
| Dividend Yield | 2.3% | Adequate | Growth focus over income |
Capital Allocation: Merck & Co., Inc. returns 3.5% shareholder yield, reducing shares 1.2% YoY
Total shareholder yield 3.5% (div 2.3% + buyback 1.2%). Share count -1.2% YoY. Capital returned $12.6B TTM. Source: 10-Q filed 2026-08-07.
| Metric | MRK | Rating | Context |
|---|---|---|---|
| Total Shareholder Yield | 3.5% | Good | Dividend + buyback yield combined |
| Buyback Yield | 1.2% | Adequate | Minimal buyback activity |
| Share Count Change (YoY) | -1.2% | Good | Net share reduction (accretive) |
| Total Capital Returned (TTM) | $12.6B | Good | Dividends + buybacks returned to shareholders |
Sector Rankings
| Metric | Value | Percentile | vs Median |
|---|---|---|---|
| Return on Invested Capital (ROIC) | 4.0% | Top 50% | - |
| Free Cash Flow Margin | 24.1% | Top 10% | 36.9x above |
| Gross Margin | 73.0% | Top 50% | 1.1x above |
| Operating Margin | 10.5% | Top 50% | - |
| Return on Equity (ROE) | 6.5% | Top 50% | - |
| P/E Ratio | 113.6x | N/A | - |
Financial Scorecard
| Metric | MRK | Rating | Sector Context |
|---|---|---|---|
| Return on Invested Capital (ROIC) | 4.0% | Warning | Top 50% of sector (median: -7.4%) |
| Free Cash Flow Margin | 24.1% | Excellent | Top 10% of sector (median: 0.7%) |
| Gross Margin | 73.0% | Excellent | Top 50% of sector (median: 63.7%) |
| Debt to Equity Ratio | 128.6% | Adequate | Elevated but manageable |
| P/E Ratio (Price-to-Earnings) | 113.6x | Warning | High expectations priced in |
| Free Cash Flow Yield | 4.5% | Adequate | Moderate yield |
Frequently Asked Questions
Q: What is Merck & Co., Inc.'s Return on Invested Capital (ROIC)?
Merck & Co., Inc. (MRK) has a trailing twelve-month Return on Invested Capital (ROIC) of 4.0%. The 8-quarter median ROIC is 16.9% with a declining trend. Sector median -7.4%. Source: 10-Q filed 2026-08-07.
Q: What is Merck & Co., Inc.'s Free Cash Flow Margin?
Merck & Co., Inc. (MRK) has a free cash flow margin of 24.1%, generating $16.1 billion in free cash flow over the trailing twelve months. Source: 10-Q filed 2026-08-07.
Q: What is Merck & Co., Inc.'s P/E ratio and how does it compare to peers?
Merck & Co., Inc. (MRK) trades at a P/E ratio of 113.6x, which is above the sector median of N/A. EV/Sales 6.1x. FCF yield 4.5%. Source: 10-Q filed 2026-08-07.
Q: Does Merck & Co., Inc. pay a dividend?
Merck & Co., Inc. (MRK) currently pays a dividend yield of 2.3%. Total shareholder yield (dividend + buybacks) 3.5%. Source: 10-Q filed 2026-08-07.
Q: How much debt does Merck & Co., Inc. have?
Merck & Co., Inc. (MRK) has a debt-to-equity ratio of 1.3x with total debt of $53.9 billion. Interest coverage 4.0x. Net debt $46.8 billion. Source: 10-Q filed 2026-08-07.
Q: What is Merck & Co., Inc.'s revenue and earnings growth?
Merck & Co., Inc. (MRK) grew revenue by 4.6% year-over-year. EPS -80.3% YoY. Source: 10-Q filed 2026-08-07.
Q: Is Merck & Co., Inc. buying back stock?
Merck & Co., Inc. (MRK) repurchased $4.2 billion of stock over the trailing twelve months. This represents a buyback yield of 1.2%. Share count -1.2% YoY. Source: 10-Q filed 2026-08-07.
Q: How does Merck & Co., Inc. compare to competitors in Healthcare?
Compared to other companies in Healthcare, Merck & Co., Inc. (MRK) shows: ROIC 4.0%, sector median -7.4% (Top 50%). FCF margin 24.1%, sector median 0.7% (Top 10%). Gross margin 73.0%, 9.2pp above sector median. These rankings are based on MetricDuck's analysis of all Healthcare companies with available SEC filings.
Q: What warning signs should I watch for with Merck & Co., Inc.?
Quantitative warning flags for Merck & Co., Inc. (MRK): 1) ROIC declining -26.8% over 8 quarters. Source: 10-Q filed 2026-08-07.
Data Source: Data sourced from 10-Q filed 2026-08-07. TTM metrics as of Q2 2026.
Methodology: Financial metrics calculated from SEC 10-K and 10-Q filings using standardized formulas. Sector comparisons use peer group based on SIC code.
Scope: This analysis covers SEC filing fundamentals — profitability, cash flow, balance sheet, and valuation metrics. For analyst estimates and price targets, consult sell-side research.
This analysis is for informational purposes only and does not constitute investment advice.